Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that herbal feed supplementation in Frieswal breeding bulls improved semen volume and motility, while significantly lowering dihydrotestosterone levels, suggesting a potential mechanism for enhancing semen quality.

This article reviews treatment-induced sexual dysfunctions related to 5-alpha-reductase inhibitors and reports no new results; it highlights the need to better define and understand this controversial topic.

This study found that young adult men with moderate to severe AGA have poorer semen quality compared to those with normal to mild AGA.

This chapter reviews the causes, prevalence, and prognosis of androgenetic alopecia and discusses treatments like topical minoxidil and systemic finasteride to stop hair loss and potentially increase hair density.

AGA causes permanent hair loss; minoxidil helps men, finasteride helps men, minoxidil somewhat helps women, estrogens/antiandrogens lack evidence for women.

Finasteride's link to depression is questionable due to study flaws and potential bias.

Authors defend finasteride-depression link, suggest detailed medical history, and call for more investigation.

Treatments for hair loss include hormone modifiers, minoxidil, and hair transplant surgery.

In this study, finasteride 1 mg demonstrated sustained efficacy over 10 years for men with androgenetic alopecia, especially in those over 30 or with higher AGA grades, with minimal side effects reported.

Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.

This article discusses the treatment of androgenetic alopecia and alopecia areata with finasteride and minoxidil but reports no new clinical results.

The authors updated recommendations on diagnosing and treating women's sexual dysfunctions, emphasizing a comprehensive assessment approach, while noting the need for further multidisciplinary research.

This study found that dutasteride increased scalp hair growth in men with male pattern hair loss, particularly at a 2.5 mg dose, and was more effective than finasteride over 24 weeks.

This study reported that finasteride 1 mg/day significantly increased hair growth and slowed hair loss in men with frontal scalp hair thinning over one year, and these benefits continued or improved in the second year.

In this study, minoxidil effectively reduced blood pressure to near normal levels in patients with malignant or accelerated hypertension resistant to conventional treatments, offering a potential alternative to nephrectomy.

This review provides updated guidelines for diagnosing and managing women's sexual dysfunctions but reports no new clinical findings; it emphasizes the need for ongoing research and long-term outcome studies.

This review discusses the increasing prevalence of erectile dysfunction in young men and emphasizes the importance of identifying specific causes for effective management, reporting no new clinical results.

This review examines recent advances in understanding the pathophysiology and molecular mechanisms of androgenetic alopecia, highlighting two major genetic risk loci, but does not report new clinical findings.

This review concluded that oral finasteride for men and topical minoxidil for both genders have the most evidence supporting their effectiveness and safety for treating androgenetic alopecia.

This review explores finasteride's effects on neuroactive steroid levels and their potential influence on disorders like depression and alcohol withdrawal but reports no new clinical findings.

This study supports the conclusion that the hormetic dose-response model is the most prevalent and fundamental model in biological and biomedical sciences, applicable to a wide range of clinical conditions.

This randomized pilot study suggests that finasteride may benefit some men with category IIIA chronic pelvic pain syndrome, although it is not recommended as monotherapy unless benign prostatic hyperplasia is also present.

This abstract discusses the unclear role of dihydrotestosterone (DHT) in postembryonic life in marsupials and possibly humans, reporting no new findings.

This review suggests that understanding the biological and molecular reasons for more severe COVID-19 in men, particularly those at risk for prostate cancer, could improve management of these patients, but reports no new results.

This article reviews the clinical, psychological, and management aspects of androgenetic alopecia in men, stating that it can be effectively managed by generalist clinicians with pharmacotherapy and surgical advancements.

This review discusses current and emerging treatments for benign prostatic hyperplasia and emphasizes the need for further research to optimize treatment selection, but reports no new clinical results.

This study found that finasteride significantly improved symptoms in CP/CPPS patients, except for voiding, unlike saw palmetto which showed no long-term benefits.

This review discusses the role of 5α-reductase enzymes in androgen action and related disorders, noting that their specific inhibitory drugs show promise for conditions like benign prostatic hypertrophy; it reports no new clinical results.

This article reviews existing treatments for male-pattern hair loss, noting that while they can slow progression, they generally achieve only partial hair regrowth.

This preliminary study suggests that finasteride may be an effective treatment option for patients with hidradenitis suppurativa, as six out of seven participants showed significant improvement.